4D Molecular Therapeutics, Inc. Operating Expenses
4D Molecular Therapeutics, Inc. (FDMT) reported Operating Expenses of $80.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $80.81M, a 35.87% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $76.67M, a 42.94% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $70.38M, a 25.41% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $61.27M, a 19.83% increase year-over-year.
- 4D Molecular Therapeutics, Inc. operating expenses for fiscal 2025 was $244.76M, a 30.27% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. operating expenses for fiscal 2024 was $187.88M, a 40.64% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. operating expenses for fiscal 2023 was $133.59M, a 18.05% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. operating expenses for fiscal 2022 was $113.16M, a 26.62% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $80.81M 10-Q · filed 2026-08-13 | $157.47M 10-Q · filed 2026-08-13 | $227.85M derived: sum of 3 quarters · filed 2026-08-13 | $289.12M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $76.67M 10-Q · filed 2026-05-07 | $147.04M derived: sum of 2 quarters · filed 2026-05-07 | $208.32M derived: sum of 3 quarters · filed 2026-05-07 | $267.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $70.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $131.65M derived: sum of 2 quarters · filed 2026-03-18 | $191.12M derived: sum of 3 quarters · filed 2026-08-13 | $244.76M 10-K · filed 2026-03-18 |
| 2025-09-30 | $61.27M 10-Q · filed 2025-11-10 | $120.75M derived: sum of 2 quarters · filed 2026-08-13 | $174.38M 10-Q · filed 2025-11-10 | $230.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $59.47M 10-Q · filed 2026-08-13 | $113.11M 10-Q · filed 2026-08-13 | $169.22M derived: sum of 3 quarters · filed 2026-08-13 | $220.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $53.63M 10-Q · filed 2026-05-07 | $109.75M derived: sum of 2 quarters · filed 2026-05-07 | $160.89M derived: sum of 3 quarters · filed 2026-05-07 | $203.35M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $56.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $107.25M derived: sum of 2 quarters · filed 2026-03-18 | $149.71M derived: sum of 3 quarters · filed 2026-03-18 | $187.88M 10-K · filed 2026-03-18 |
| 2024-09-30 | $51.13M 10-Q · filed 2025-11-10 | $93.60M derived: sum of 2 quarters · filed 2025-11-10 | $131.76M 10-Q · filed 2025-11-10 | $168.39M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $42.46M 10-Q · filed 2025-08-11 | $80.63M 10-Q · filed 2025-08-11 | $117.26M derived: sum of 3 quarters · filed 2025-08-11 | $151.44M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $38.16M 10-Q · filed 2025-05-08 | $74.80M derived: sum of 2 quarters · filed 2025-05-08 | $108.97M derived: sum of 3 quarters · filed 2025-05-08 | $141.35M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $36.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $70.81M derived: sum of 2 quarters · filed 2025-02-28 | $103.19M derived: sum of 3 quarters · filed 2025-02-28 | $133.59M 10-K · filed 2025-02-28 |
| 2023-09-30 | $34.18M 10-Q · filed 2024-11-13 | $66.55M derived: sum of 2 quarters · filed 2024-11-13 | $96.96M 10-Q · filed 2024-11-13 | $126.92M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $32.38M 10-Q · filed 2024-08-08 | $62.78M 10-Q · filed 2024-08-08 | $92.75M derived: sum of 3 quarters · filed 2024-08-08 | $119.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $30.40M 10-Q · filed 2024-05-09 | $60.37M derived: sum of 2 quarters · filed 2024-05-09 | $87.37M derived: sum of 3 quarters · filed 2024-05-09 | $115.95M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $29.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $56.96M derived: sum of 2 quarters · filed 2024-02-29 | $85.55M derived: sum of 3 quarters · filed 2024-02-29 | $113.16M 10-K · filed 2024-02-29 |
| 2022-09-30 | $27.00M 10-Q · filed 2023-11-09 | $55.58M derived: sum of 2 quarters · filed 2023-11-09 | $83.19M 10-Q · filed 2023-11-09 | $108.05M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $28.59M 10-Q · filed 2023-08-09 | $56.20M 10-Q · filed 2023-08-09 | $81.06M derived: sum of 3 quarters · filed 2023-08-09 | $105.08M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $27.61M 10-Q · filed 2023-05-11 | $52.47M derived: sum of 2 quarters · filed 2023-05-11 | $76.49M derived: sum of 3 quarters · filed 2023-05-11 | $98.67M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $24.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $48.88M derived: sum of 2 quarters · filed 2023-03-15 | $71.06M derived: sum of 3 quarters · filed 2023-03-15 | $89.37M 10-K · filed 2023-03-15 |
| 2021-09-30 | $24.03M 10-Q · filed 2022-11-08 | $46.20M derived: sum of 2 quarters · filed 2022-11-08 | $64.52M 10-Q · filed 2022-11-08 | $83.96M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $22.18M 10-Q · filed 2022-08-11 | $40.49M 10-Q · filed 2022-08-11 | $59.93M derived: sum of 3 quarters · filed 2022-08-11 | $75.17M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $18.31M 10-Q · filed 2022-05-12 | $37.76M derived: sum of 2 quarters · filed 2022-05-12 | $52.99M derived: sum of 3 quarters · filed 2022-05-12 | $71.78M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $34.68M derived: sum of 2 quarters · filed 2022-03-28 | $53.46M derived: sum of 3 quarters · filed 2022-03-28 | $70.28M 10-K · filed 2022-03-28 |
| 2020-09-30 | $15.24M 10-Q · filed 2021-11-10 | $34.02M derived: sum of 2 quarters · filed 2021-11-10 | $50.83M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.78M 10-Q · filed 2021-08-12 | $35.59M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $16.81M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $57.75M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |